In an industry where the wrong manufacturing partnership can derail a drug program, and the right one can accelerate it, biotech leaders face mounting pressure to make smarter, faster decisions about their CDMOs. But are they asking the right questions?
The 2026 J.P. Morgan Healthcare Conference revealed a shift in global pharmaceutical power dynamics, with China’s biotech sector commanding ever increasing attention from Western investors and executives who acknowledged the region’s transformation from manufacturing hub to innovation leader. You Cannot
“Life has not become simpler and easier. It’s become more complex. Success requires acknowledging this complexity early and building flexibility into every aspect of the business model.” Renée Aguiar-Lucander is the CEO of Hansa Biopharma, appointed in April 2025. Renée
“CDMOs are partners with deep, extensive technical expertise that can be leveraged strategically—not just a restaurant where you pick from a menu.” Marta Kijanka, founder of MK Bioconsultancy, is a strategic project manager and CMC consultant who guides early-stage biotech
As the pharmaceutical industry grapples with geopolitical tensions, regulatory shifts, and technological disruption, the question of what constitutes a strong external partnership has never been more critical. We asked industry leaders across CDMOs, biotechs, and technology providers to share their
Manufacturing strategy has become a critical differentiator in biotech funding rounds, directly impacting company valuation and exit opportunities. This guide helps biotech leaders prepare for investor scrutiny of their manufacturing approach, ensuring your strategy demonstrates both operational maturity and commercial
For early-stage biotechs that have reached the major milestone of obtaining capital, it is critical to transition from fundraising to drug product development as quickly as possible. At CDMO Live 2024, Ray Sison, managing partner for SCxCMC explained how to
Bernardo Estupiñán has a career spanning chemistry and business development, and now working as a consultant to guide companies developing new biopharmaceuticals through contract manufacturing. In this interview he shares his advice for how biotechs can successfully navigate the contract
“CDMOs and Biotechs will both die,” warns NKILT Therapeutics CEO as he talks candidly about the funding crisis stalling cell therapy development, predicting widespread consolidation across biotechs and CDMOs unless the industry shifts toward risk-sharing partnership models that align manufacturing
“Projects quite often realize too late that their R&D process cannot just be copy-pasted from the lab into the manufacturing facility.” Dr. Jenny Prange is Head of Project Management at the Regenerative Medicine Technologies Platform (RMTP) at Wiz Zurich, an
